These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 10202927)

  • 1. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury.
    Sawa T; Yahr TL; Ohara M; Kurahashi K; Gropper MA; Wiener-Kronish JP; Frank DW
    Nat Med; 1999 Apr; 5(4):392-8. PubMed ID: 10202927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
    Moriyama K; Wiener-Kronish JP; Sawa T
    Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge.
    Neely AN; Holder IA; Wiener-Kronish JP; Sawa T
    Burns; 2005 Mar; 31(2):153-8. PubMed ID: 15683685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PcrV antibody protects multi-drug resistant Pseudomonas aeruginosa induced acute lung injury.
    Wang Q; Li H; Zhou J; Zhong M; Zhu D; Feng N; Liu F; Bai C; Song Y
    Respir Physiol Neurobiol; 2014 Mar; 193():21-8. PubMed ID: 24418353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV.
    Frank DW; Vallis A; Wiener-Kronish JP; Roy-Burman A; Spack EG; Mullaney BP; Megdoud M; Marks JD; Fritz R; Sawa T
    J Infect Dis; 2002 Jul; 186(1):64-73. PubMed ID: 12089663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by Pseudomonas aeruginosa.
    Golpasha ID; Mousavi SF; Owlia P; Siadat SD; Irani S
    Bosn J Basic Med Sci; 2015 May; 15(2):15-24. PubMed ID: 26042508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.
    Sawa T; Ito E; Nguyen VH; Haight M
    Hum Vaccin Immunother; 2014; 10(10):2843-52. PubMed ID: 25483637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polarisation of type III translocation by Pseudomonas aeruginosa requires PcrG, PcrV and PopN.
    Sundin C; Thelaus J; Bröms JE; Forsberg A
    Microb Pathog; 2004 Dec; 37(6):313-22. PubMed ID: 15619427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/PopD translocation pore in host cell membranes.
    Goure J; Pastor A; Faudry E; Chabert J; Dessen A; Attree I
    Infect Immun; 2004 Aug; 72(8):4741-50. PubMed ID: 15271936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa.
    Shime N; Sawa T; Fujimoto J; Faure K; Allmond LR; Karaca T; Swanson BL; Spack EG; Wiener-Kronish JP
    J Immunol; 2001 Nov; 167(10):5880-6. PubMed ID: 11698464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa.
    Saha S; Takeshita F; Sasaki S; Matsuda T; Tanaka T; Tozuka M; Takase K; Matsumoto T; Okuda K; Ishii N; Yamaguchi K; Klinman DM; Xin KQ; Okuda K
    Vaccine; 2006 Sep; 24(37-39):6240-9. PubMed ID: 16806598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia.
    Naito Y; Hamaoka S; Kinoshita M; Kainuma A; Shimizu M; Katoh H; Moriyama K; Ishii KJ; Sawa T
    Microbiol Immunol; 2018 Dec; 62(12):774-785. PubMed ID: 30378708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models.
    Ranjbar M; Behrouz B; Norouzi F; Mousavi Gargari SL
    Mol Immunol; 2019 Dec; 116():98-105. PubMed ID: 31634816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further characterization of a type III secretion system (T3SS) and of a new effector protein from a clinical isolate of Aeromonas hydrophila--part I.
    Sha J; Wang SF; Suarez G; Sierra JC; Fadl AA; Erova TE; Foltz SM; Khajanchi BK; Silver A; Graf J; Schein CH; Chopra AK
    Microb Pathog; 2007 Oct; 43(4):127-46. PubMed ID: 17644303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model.
    Imamura Y; Yanagihara K; Fukuda Y; Kaneko Y; Seki M; Izumikawa K; Miyazaki Y; Hirakata Y; Sawa T; Wiener-Kronish JP; Kohno S
    Eur Respir J; 2007 May; 29(5):965-8. PubMed ID: 17301098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
    Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T
    Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Live
    Aguilera-Herce J; García-Quintanilla M; Romero-Flores R; McConnell MJ; Ramos-Morales F
    mSphere; 2019 Apr; 4(2):. PubMed ID: 30996108
    [No Abstract]   [Full Text] [Related]  

  • 19. Type III secretion proteins PcrV and PcrG from Pseudomonas aeruginosa form a 1:1 complex through high affinity interactions.
    Nanao M; Ricard-Blum S; Di Guilmi AM; Lemaire D; Lascoux D; Chabert J; Attree I; Dessen A
    BMC Microbiol; 2003 Oct; 3():21. PubMed ID: 14565848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia.
    Hamaoka S; Naito Y; Katoh H; Shimizu M; Kinoshita M; Akiyama K; Kainuma A; Moriyama K; Ishii KJ; Sawa T
    Microbiol Immunol; 2017 Feb; 61(2):64-74. PubMed ID: 28370521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.